Enveric Biosciences, Inc. Stock price

Equities

ENVB

US29405E2081

Biotechnology & Medical Research

Market Closed - Nasdaq 04:00:00 2024-03-28 pm EDT 5-day change 1st Jan Change
1 USD -1.96% Intraday chart for Enveric Biosciences, Inc. -14.53% -23.08%
Sales 2024 * - Sales 2025 * 5M Capitalization 7.44M
Net income 2024 * -18M Net income 2025 * -15M EV / Sales 2024 * -
Net cash position 2024 * - Net cash position 2025 * - EV / Sales 2025 * 1.49 x
P/E ratio 2024 *
-0.38 x
P/E ratio 2025 *
-1.59 x
Employees 26
Yield 2024 *
-
Yield 2025 *
-
Free-Float 66.94%
More Fundamentals * Assessed data
Dynamic Chart
1 day-1.96%
1 week-14.53%
Current month-31.03%
1 month+19.05%
3 months-23.22%
6 months-56.71%
Current year-23.08%
More quotes
1 week
1.00
Extreme 1
1.20
1 month
1.00
Extreme 1
2.92
Current year
0.65
Extreme 0.649
2.92
1 year
0.65
Extreme 0.649
6.98
3 years
0.65
Extreme 0.649
187.00
5 years
0.65
Extreme 0.649
350.00
10 years
0.65
Extreme 0.649
350.00
More quotes
Managers TitleAgeSince
Chief Executive Officer 55 21-09-15
Director of Finance/CFO 60 23-03-12
Chief Tech/Sci/R&D Officer - 23-02-21
Members of the board TitleAgeSince
Chairman 66 22-06-12
Director/Board Member 64 21-03-16
Chief Executive Officer 55 21-09-15
More insiders
Date Price Change Volume
24-03-28 1 -1.96% 266,692
24-03-27 1.02 -3.77% 389,193
24-03-26 1.06 +0.95% 306,184
24-03-25 1.05 -7.08% 445,030
24-03-22 1.13 -3.42% 298,506

Delayed Quote Nasdaq, March 28, 2024 at 04:00 pm EDT

More quotes
Enveric Biosciences, Inc. is a biotechnology company. The Company is engaged in the development of novel small-molecule therapeutics for the treatment of anxiety, depression and addiction disorders. The Company through Psybrary has created a robust intellectual property (IP) portfolio of New Chemical Entities (NCEs) for specific mental health indications or physical ailments. The Company's lead program, EB-373, is a next-generation prodrug of psilocin, the active metabolite of psilocybin. EB-373 is a drug candidate from the EVM201 Series advancing through preclinical development for the treatment of anxiety disorders. The Company is also advancing its third generation of therapeutics, the EVM301 Series, that eliminates the psychedelic experience and removes unwanted effects, reducing safety concerns, and hence offering a novel and holistic approach for treating central nervous system disorders.
More about the company
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
1 USD
Average target price
9 USD
Spread / Average Target
+800.00%
Consensus
  1. Stock
  2. Equities
  3. Stock Enveric Biosciences, Inc. - Nasdaq